Health care equities advanced alongside the broader market during Monday morning trading. By 9:58 a.m. ET, the State Street Health Care Select Sector SPDR ETF recorded a 0.88% increase to reach $186.42, while the S&P 500 climbed 1.70% to 7,501.96. The sector ETF had closed at $184.80 on Friday, following a 52-week high of $192.32 achieved on November 5, 2026. This market activity coincides with Medicare Open Enrollment, spanning from October 15, 2026, to December 7, 2026.
Ahead of Open Enrollment, the Centers for Medicare & Medicaid Services (CMS) issued its projections for 2027. CMS estimated that the weighted average monthly premium across all Medicare Advantage plans will decline by 16.5%, falling from $14.37 in 2026 to $12.00 in 2027. Additionally, the total average monthly Part D premium for stand-alone prescription drug plans is projected to rise by less than $1, moving from $35.09 in 2026 to $36 in 2027. Amid these developments, several prominent companies across pharmaceuticals, biotechnology, health insurance, medical devices, and drug distribution delivered quarterly updates or regulatory milestones, with four out of five key firms raising their full-year guidance.
Johnson & Johnson (NYSE: JNJ) announced on November 5 that the U.S. Food and Drug Administration (FDA) granted accelerated approval for RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) as a single agent. The therapy is indicated for treating adult patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) whose disease progressed on or following platinum-based chemotherapy and an anti-PD-(L)1 antibody. The indication excludes patients with HPV-associated oropharyngeal squamous cell carcinoma (OPSCC). This marks the first approval of a dual-targeted therapy for this setting, based on the Phase 1b/2 OrigAMI-4 trial which demonstrated a confirmed overall response rate of 42 percent per blinded independent central review. Continued approval depends on verification in the ongoing Phase 3 OrigAMI-5 study.
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) reported third-quarter total revenue of $3.44 billion, representing a 12% increase compared to the third quarter of 2025, driven by cystic fibrosis therapies and diversification into new disease areas. GAAP net income was $654 million, down from $1.1 billion in the prior-year period due to expenses from the Crinetics Pharmaceuticals acquisition, which closed on September 1. Vertex raised its full-year 2026 total revenue guidance to a range of $13.15 billion to $13.25 billion, up from $13.1 billion to $13.2 billion previously. Furthermore, the FDA is reviewing the BLA submission for accelerated approval of povetacicept in IgA nephropathy under priority review, with a PDUFA target action date set for November 30, 2026.
Humana Inc. (NYSE: HUM) reported third-quarter GAAP earnings per share of $1.33 and an adjusted loss per share of $0.70 on November 6. GAAP revenues reached $41,155 million, compared to $32,649 million a year earlier, and the Insurance segment GAAP benefit ratio stood at 93.7 percent. Humana raised its full-year 2026 adjusted EPS guidance to at least $9.50, up from the prior expectation of at least $9.00, while noting that guidance accounts for Star Ratings headwinds for Bonus Year 2026 net of mitigation. The company also posted year-to-date patient growth of 146,800 in CenterWell Senior Primary Care and Medicaid membership growth of 103,600.
Edwards Lifesciences Corporation (NYSE: EW) announced on November 4 that third-quarter sales grew 10.5% to $1.72 billion, with constant currency sales up 11.2%. Transcatheter aortic valve replacement (TAVR) sales rose 8.0% to $1.24 billion, and adjusted sales of transcatheter mitral and tricuspid therapies (TMTT) grew 44.0% to $207 million. The company raised its constant currency total sales growth guidance to approximately 11.5% from 10% to 11% and adjusted EPS guidance to $2.97 to $3.05. Edwards also noted the release of an updated national coverage determination for TAVR by CMS and FDA approval of the PASCAL Precision system in October.
McKesson Corporation (NYSE: MCK) reported fiscal 2027 second-quarter consolidated revenues of $111.0 billion, an 8% increase, alongside earnings per diluted share of $10.44 and adjusted earnings per diluted share of $11.68, reflecting an 18% increase. The company raised its fiscal 2027 adjusted earnings per diluted share guidance range to $45.60 to $46.40 from the previous range of $44.20 to $45.00. The revenue growth was attributed to the North American Pharmaceutical and Oncology & Multispecialty segments. Additionally, McKesson completed the acquisition of Precision Medicine Group, LLC on November 2 to advance its biopharma services and oncology strategy.
